Skip to content

Study · Non-randomized trial · n = 10 · 1997

3 results

Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.

Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmieri R, Gennari C

Clinical endocrinology1 Jan 1997Cited by 16 (Europe PMC)

PMID9059558 (opens in a new tab)DOI10.1046/j.1365-2265.1997.d01-1750.x (opens in a new tab)PepBankPUB-09059558
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, lumbar spine BMD significantly decreased during calcitonin preceded by placebo.

    In plain wordsIn women with osteoporosis, spine bone density decreased during calcitonin treatment preceded by placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseLumbar spine BMD
    Study

    n = 10

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 IU/day · subcutaneous · 21 days per cycle for 24 monthsAs given in this study (human).

    Measurements

    P value
    < 0.05
    lumbar spine BMD decrease in group 2

    Source sentences

    Summary
    in contrast, significant (P < 0.05) decreases in BMD-LS values were found in patients treated with CT and placebo (group 2) and with GH and placebo (group 3).
    2 context sentences
    Summary · context
    placebo for 7 days, followed by sCT for 21 days and by 61 days without treatment (group 2);
    Summary · context
    Each cycle was repeated 8 times (24 months).
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, femoral shaft BMD did not significantly change with calcitonin preceded by placebo.

    In plain wordsIn women with osteoporosis, thigh bone density did not significantly change with calcitonin preceded by placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeFemoral shaft BMD
    Study

    n = 10

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 IU/day · subcutaneous · 21 days per cycle for 24 monthsAs given in this study (human).

    Source sentences

    Summary
    BMD-F did not show any significant change in patients of group 2, but a significant (P < 0.05) decrease was found in groups 1 and 3.
    2 context sentences
    Summary · context
    placebo for 7 days, followed by sCT for 21 days and by 61 days without treatment (group 2);
    Summary · context
    Each cycle was repeated 8 times (24 months).
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with postmenopausal osteoporosis, distal radius BMD did not significantly change with calcitonin preceded by placebo.

    In plain wordsIn women with osteoporosis, wrist bone density did not significantly change with calcitonin preceded by placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeDistal radius BMD
    Study

    n = 10

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50 IU/day · subcutaneous · 21 days per cycle for 24 monthsAs given in this study (human).

    Source sentences

    Summary
    BMD-DR did not show any significant change with respect to baseline in any of the three groups.
    2 context sentences
    Summary · context
    placebo for 7 days, followed by sCT for 21 days and by 61 days without treatment (group 2);
    Summary · context
    Each cycle was repeated 8 times (24 months).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.